BR112018073549A2 - tratamento de lesões de pele - Google Patents
tratamento de lesões de peleInfo
- Publication number
- BR112018073549A2 BR112018073549A2 BR112018073549-3A BR112018073549A BR112018073549A2 BR 112018073549 A2 BR112018073549 A2 BR 112018073549A2 BR 112018073549 A BR112018073549 A BR 112018073549A BR 112018073549 A2 BR112018073549 A2 BR 112018073549A2
- Authority
- BR
- Brazil
- Prior art keywords
- skin injury
- injury treatment
- formula
- treatment
- tautomers
- Prior art date
Links
- 208000028990 Skin injury Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 206010040882 skin lesion Diseases 0.000 abstract 1
- 231100000444 skin lesion Toxicity 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- -1 tautomers Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a presente invenção refere-se a um composto da fórmula (i), (i) com a condição de que pelo menos um dentre r1 e r2 é uma morfolinila de fórmula ii; (ii) e profármacos, metabólitos, tautômeros, solvatos e sais farmaceuticamente aceitáveis dos mesmos, para uso na prevenção ou no tratamento de uma lesão de pele em um sujeito.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662338111P | 2016-05-18 | 2016-05-18 | |
US62/338,111 | 2016-05-18 | ||
EP17151843 | 2017-01-17 | ||
EP17151843.4 | 2017-01-17 | ||
PCT/EP2017/025137 WO2017198347A1 (en) | 2016-05-18 | 2017-05-17 | Treatment of skin lesions |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018073549A2 true BR112018073549A2 (pt) | 2019-03-19 |
BR112018073549A8 BR112018073549A8 (pt) | 2023-01-10 |
Family
ID=65463390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018073549A BR112018073549A8 (pt) | 2016-05-18 | 2017-05-17 | Uso de inibidores seletivos e específicos de mtor e/ou de inibidores duplos de pi3k/mtor, e composição farmacêutica |
Country Status (9)
Country | Link |
---|---|
US (2) | US10993947B2 (pt) |
JP (3) | JP7118509B2 (pt) |
KR (1) | KR102483630B1 (pt) |
CN (1) | CN109414415B (pt) |
BR (1) | BR112018073549A8 (pt) |
IL (1) | IL263076B (pt) |
MX (1) | MX2018014167A (pt) |
RU (1) | RU2018140001A (pt) |
ZA (1) | ZA201807325B (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018014168A (es) * | 2016-05-18 | 2019-04-29 | Piqur Therapeutics Ag | Tratamiento de transtornos neurologicos. |
IL274132B2 (en) * | 2017-11-23 | 2024-02-01 | Piqur Therapeutics Ag | Treatment of skin problems |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
MX2008010221A (es) | 2006-02-09 | 2009-03-05 | Alba Therapeutics Corp | Formulaciones para un efector de union ajustada. |
ATE551334T1 (de) | 2007-02-06 | 2012-04-15 | Novartis Ag | Pi3-kinase-hemmer und verfahren zu ihrer verwendung |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
WO2012099968A1 (en) * | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating skin cancer associated diseases |
WO2012101654A2 (en) | 2011-01-25 | 2012-08-02 | Sphaera Pharma Pvt. Ltd | Novel triazine compounds |
JP2014505107A (ja) * | 2011-02-11 | 2014-02-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 過誤腫性腫瘍細胞を阻害する方法 |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
WO2014090147A1 (zh) * | 2012-12-14 | 2014-06-19 | 上海恒瑞医药有限公司 | 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
US20150065431A1 (en) | 2013-08-27 | 2015-03-05 | Northwestern University | Reducing cutaneous scar formation and treating skin conditions |
CN103483345B (zh) * | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
CN104557871B (zh) * | 2013-10-28 | 2017-05-03 | 上海汇伦生命科技有限公司 | 具有螺环取代基的芳基吗啉类化合物,其制备方法和用途 |
AU2015250994B2 (en) | 2014-04-22 | 2018-12-20 | Torqur Ag | Novel manufacturing process for triazine, pyrimidine and pyridine derivatives |
AU2015266191A1 (en) | 2014-05-27 | 2016-09-15 | Almirall, S.A. | Medical use |
CA2953392A1 (en) * | 2014-06-30 | 2016-01-07 | Baxter Corporation Englewood | Managed medical information exchange |
MA40933A (fr) * | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
MX2018014168A (es) | 2016-05-18 | 2019-04-29 | Piqur Therapeutics Ag | Tratamiento de transtornos neurologicos. |
-
2017
- 2017-05-17 US US16/301,728 patent/US10993947B2/en active Active
- 2017-05-17 BR BR112018073549A patent/BR112018073549A8/pt active Search and Examination
- 2017-05-17 JP JP2018560667A patent/JP7118509B2/ja active Active
- 2017-05-17 RU RU2018140001A patent/RU2018140001A/ru not_active Application Discontinuation
- 2017-05-17 KR KR1020187036446A patent/KR102483630B1/ko active IP Right Grant
- 2017-05-17 MX MX2018014167A patent/MX2018014167A/es unknown
- 2017-05-17 CN CN201780029947.7A patent/CN109414415B/zh active Active
-
2018
- 2018-11-01 ZA ZA2018/07325A patent/ZA201807325B/en unknown
- 2018-11-18 IL IL263076A patent/IL263076B/en unknown
-
2021
- 2021-03-26 US US17/214,309 patent/US11918586B2/en active Active
-
2022
- 2022-03-29 JP JP2022052911A patent/JP7464645B2/ja active Active
-
2024
- 2024-01-11 JP JP2024002206A patent/JP2024050600A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102483630B1 (ko) | 2023-01-02 |
RU2018140001A (ru) | 2020-06-18 |
CN109414415A (zh) | 2019-03-01 |
JP2019515020A (ja) | 2019-06-06 |
US10993947B2 (en) | 2021-05-04 |
MX2018014167A (es) | 2019-08-16 |
CN109414415B (zh) | 2023-05-02 |
US11918586B2 (en) | 2024-03-05 |
JP7118509B2 (ja) | 2022-08-16 |
JP7464645B2 (ja) | 2024-04-09 |
IL263076B (en) | 2022-02-01 |
JP2024050600A (ja) | 2024-04-10 |
JP2022088520A (ja) | 2022-06-14 |
KR20190026668A (ko) | 2019-03-13 |
US20210361665A1 (en) | 2021-11-25 |
ZA201807325B (en) | 2019-08-28 |
BR112018073549A8 (pt) | 2023-01-10 |
US20190290653A1 (en) | 2019-09-26 |
IL263076A (en) | 2018-12-31 |
RU2018140001A3 (pt) | 2020-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
UY37847A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
CL2017001124A1 (es) | Agentes inmunomoduladores | |
BR112018072570A2 (pt) | piperidinas como inibidores de menina | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
BR112018070859A2 (pt) | degradantes da proteína de bet | |
BR112019002576A2 (pt) | composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo | |
BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
BR112018014675A2 (pt) | novos derivados de cianoindolina substituída como inibidores de nik | |
BR112018011700A2 (pt) | ?moduladores de canais de kv3 para tratar dor? | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112019020421A8 (pt) | Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres | |
BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
PH12020550583A1 (en) | Use of riluzole prodrugs to treat ataxias | |
BR112023014973A2 (pt) | Derivados de urolitina e métodos de uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) ; TORQUR AG (CH) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |